1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. ArQule Acquires Camitro

M&A Deal Summary

ArQule Acquires Camitro

On January 29, 2001, ArQule acquired life science company Camitro for 76M USD

Acquisition Highlights
  • This is ArQule’s 1st transaction in the Life Science sector.
  • This is ArQule’s largest (disclosed) transaction.
  • This is ArQule’s 1st transaction in the United States.
  • This is ArQule’s 1st transaction in California.

M&A Deal Summary
Date 2001-01-29
Target Camitro
Sector Life Science
Buyer(s) ArQule
Deal Type Add-on Acquisition
Deal Value 76M USD

Target

Camitro

Menlo Park, California, United States
Camitro Corp., is a predictive modeling company. Camitro's technology consisted of an integrated platform of predictive models and strategies for the design, selection, and optimization of potential new pharmaceutical drugs.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

ArQule

Burlington, Massachusetts, United States
Category Company
Founded 1993
Sector Life Science
Employees38
Revenue 26M USD (2018)
DESCRIPTION

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. ArQule's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule was formed in 1993 and is based in Burlington, Massachusetts.

DEAL STATS #
Overall 1 of 2
Sector: Life Science M&A 1 of 2
Type: Add-on Acquisition M&A Deals 1 of 2
State: California M&A 1 of 1
Country: United States M&A 1 of 2
Year: 2001 M&A 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2003-07-17 Cyclis Pharmaceuticals

Norwood, Massachusetts, United States

Cyclis is discovering and developing small-molecule cancer drugs based on a novel technology designed to selectively kill cancer cells and preserve normal cells by restoring and activating cellular checkpoints known to be defective in cancers.

Buy $25M
Mergr

Solution for

Product

Company

Legal